Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer’s disease

Acta Neuropathologica

Volumn 132, Issue 2, 2016, Pages 225-234

  Shinohara, Mitsuru ^a   Murray, Melissa E ^a   Frank, Ryan D ^b   Shinohara, Motoko ^a   DeTure, Michael ^a   Yamazaki, Yu ^a   Tachibana, Masaya ^a   Atagi, Yuka ^a   Davis, Mary D ^a   Liu, Chia Chen ^a   Zhao, Na ^a   Painter, Meghan M ^a   Petersen, Ronald C ^c   Fryer, John D ^a   Crook, Julia E ^b   Dickson, Dennis W ^a   Bu, Guojun ^a   Kanekiyo, Takahisa ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Alzheimer s disease; Amyloid ; APOE; Cerebral amyloid angiopathy; Sex

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN A4; APOLIPOPROTEIN E; APOLIPOPROTEIN E4;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BIOCHEMICAL ANALYSIS; BRAIN LEVEL; BRAIN TISSUE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; INCIDENCE; INFERIOR PARIETAL CORTEX; MAJOR CLINICAL STUDY; MALE; MEDIAL FRONTAL CORTEX; MOLECULE; MOTOR CORTEX; NEUROFIBRILLARY TANGLE; PATHOGENESIS; PRIORITY JOURNAL; SEX DIFFERENCE; TEMPORAL CORTEX; VASCULAR AMYLOIDOSIS; VERY ELDERLY; VISUAL CORTEX; AMYLOID PLAQUE; BRAIN; GENETICS; METABOLISM; PATHOLOGY; SEXUAL DEVELOPMENT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; FEMALE; GENOTYPE; HUMANS; MALE; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID; SEX CHARACTERISTICS;

EID: 84968531504     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-016-1580-y     Document Type: Article

References (51)

1. Altmann A, Tian L, Henderson VW, Greicius MD (2014) Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol 75:563–573. doi:10.1002/ana.24135
2. Alzheimer’sAssociation (2015) 2015 Alzheimer’s disease facts and figures. Alzheimer’s Dement 11:332–384
3. Attems J (2005) Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol 110:345–359. doi:10.1007/s00401-005-1074-9
4. Bakker EN, Bacskai BJ, Arbel-Ornath M, Aldea R, Bedussi B, Morris AW, Weller RO, Carare RO (2016) Lymphatic clearance of the brain: perivascular, paravascular and significance for neurodegenerative diseases. Cell Mol Neurobiol. doi:10.1007/s10571-015-0273-8
5. Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA (2005) Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry 62:685–691. doi:10.1001/archpsyc.62.6.685
6. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J et al (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485:512–516. doi:10.1038/nature11087
7. Biffi A, Sonni A, Anderson CD, Kissela B, Jagiella JM, Schmidt H, Jimenez-Conde J, Hansen BM, Fernandez-Cadenas I, Cortellini L et al (2010) Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol 68:934–943. doi:10.1002/ana.22134
8. Bu G (2009) Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10:333–344. doi:10.1038/nrn2620
9. Carter CL, Resnick EM, Mallampalli M, Kalbarczyk A (2012) Sex and gender differences in Alzheimer’s disease: recommendations for future research. J Womens Health (Larchmt) 21:1018–1023. doi:10.1089/jwh.2012.3789
10. Corder EH, Ghebremedhin E, Taylor MG, Thal DR, Ohm TG, Braak H (2004) The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci 1019:24–28. doi:10.1196/annals.1297.005
11. de la Torre JC (2002) Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33:1152–1162
12. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman A (1996) Cerebral amyloid angiopathy in the brains of patients with Alzheimer’s disease: the CERAD experience, part XV. Neurology 46:1592–1596
13. Esiri M, Chance S, Joachim C, Warden D, Smallwood A, Sloan C, Christie S, Wilcock G, Smith AD (2015) Cerebral amyloid angiopathy, subcortical white matter disease and dementia: literature review and study in OPTIMA. Brain Pathol 25:51–62. doi:10.1111/bpa.12221
14. Filippini N, Ebmeier KP, MacIntosh BJ, Trachtenberg AJ, Frisoni GB, Wilcock GK, Beckmann CF, Smith SM, Matthews PM, Mackay CE (2011) Differential effects of the APOE genotype on brain function across the lifespan. Neuroimage 54:602–610. doi:10.1016/j.neuroimage.2010.08.009
15. Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM (2005) Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci 25:2803–2810. doi:10.1523/JNEUROSCI.5170-04.2005
16. Gahr M, Nowak DA, Connemann BJ, Schonfeldt-Lecuona C (2013) Cerebral Amyloidal Angiopathy—a disease with implications for neurology and psychiatry. Brain Res 1519:19–30. doi:10.1016/j.brainres.2013.04.052
17. Gravina SA, Ho L, Eckman CB, Long KE, Otvos L Jr, Younkin LH, Suzuki N, Younkin SG (1995) Amyloid beta protein (A beta) in Alzheimer’s disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 270:7013–7016
18. Greenberg SM, Al-Shahi Salman R, Biessels GJ, van Buchem M, Cordonnier C, Lee JM, Montaner J, Schneider JA, Smith EE, Vernooij M et al (2014) Outcome markers for clinical trials in cerebral amyloid angiopathy. Lancet Neurol 13:419–428. doi:10.1016/S1474-4422(14)70003-1
19. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41:1088–1093. doi:10.1038/ng.440
20. Herzig MC, Van Nostrand WE, Jucker M (2006) Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. Brain Pathol 16:40–54
21. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148:1204–1222. doi:10.1016/j.cell.2012.02.040
22. Kanekiyo T, Xu H, Bu G (2014) ApoE and Abeta in Alzheimer’s disease: accidental encounters or partners? Neuron 81:740–754. doi:10.1016/j.neuron.2014.01.045
23. Krause DN, Duckles SP (1985) Pelligrino DA (2006) Influence of sex steroid hormones on cerebrovascular function. J Appl Physiol 101:1252–1261. doi:10.1152/japplphysiol.01095.2005
24. La Porte SL, Bollini SS, Lanz TA, Abdiche YN, Rusnak AS, Ho WH, Kobayashi D, Harrabi O, Pappas D, Mina EW et al (2012) Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer’s disease. J Mol Biol 421:525–536. doi:10.1016/j.jmb.2011.11.047
25. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 41:1094–1099. doi:10.1038/ng.439
26. Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106–118. doi:10.1038/nrneurol.2012.263
27. Maia LF, Mackenzie IR, Feldman HH (2007) Clinical phenotypes of cerebral amyloid angiopathy. J Neurol Sci 257:23–30. doi:10.1016/j.jns.2007.01.054
28. Mandybur TI (1986) Cerebral amyloid angiopathy: the vascular pathology and complications. J Neuropathol Exp Neurol 45:79–90
29. Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, Iqbal K (1993) Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer’s disease. Arch Biochem Biophys 301:41–52. doi:10.1006/abbi.1993.1112
30. Morris AW, Sharp MM, Albargothy NJ, Fernandes R, Hawkes CA, Verma A, Weller RO, Carare RO (2016) Vascular basement membranes as pathways for the passage of fluid into and out of the brain. Acta Neuropathol. doi:10.1007/s00401-016-1555-z
31. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW (2011) Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 10:785–796. doi:10.1016/S1474-4422(11)70156-9
32. Nelson PT, Pious NM, Jicha GA, Wilcock DM, Fardo DW, Estus S, Rebeck GW (2013) APOE-epsilon2 and APOE-epsilon4 correlate with increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp Neurol 72:708–715. doi:10.1097/NEN.0b013e31829a25b9
33. Nicoll JA, Burnett C, Love S, Graham DI, Dewar D, Ironside JW, Stewart J, Vinters HV (1997) High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol 41:716–721. doi:10.1002/ana.410410607
34. Petrea RE, Beiser AS, Seshadri S, Kelly-Hayes M, Kase CS, Wolf PA (2009) Gender differences in stroke incidence and poststroke disability in the Framingham heart study. Stroke 40:1032–1037. doi:10.1161/STROKEAHA.108.542894
35. Pu Y, Liu L, Wang Y, Zou X, Pan Y, Soo Y, Leung T, Zhao X, Wong KS (2013) Geographic and sex difference in the distribution of intracranial atherosclerosis in China. Stroke 44:2109–2114. doi:10.1161/STROKEAHA.113.001522
36. Rannikmae K, Kalaria RN, Greenberg SM, Chui HC, Schmitt FA, Samarasekera N, Al-Shahi Salman R, Sudlow CL (2014) APOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysis. J Neurol Neurosurg Psychiatry 85:300–305. doi:10.1136/jnnp-2013-306485
37. Rensink AA, de Waal RM, Kremer B, Verbeek MM (2003) Pathogenesis of cerebral amyloid angiopathy. Brain Res Brain Res Rev 43:207–223
38. Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, Holton JL (2003) Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 62:885–898
39. Ringman JM, Sachs MC, Zhou Y, Monsell SE, Saver JL, Vinters HV (2014) Clinical predictors of severe cerebral amyloid angiopathy and influence of APOE genotype in persons with pathologically verified Alzheimer disease. JAMA Neurol 71:878–883. doi:10.1001/jamaneurol.2014.681
40. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:9649–9653
41. Selkoe DJ (2002) Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest 110:1375–1381. doi:10.1172/JCI16783
42. Shinohara M, Fujioka S, Murray ME, Wojtas A, Baker M, Rovelet-Lecrux A, Rademakers R, Das P, Parisi JE, Graff-Radford NR et al (2014) Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer’s disease. Brain 137:1533–1549. doi:10.1093/brain/awu046
43. Shinohara M, Petersen RC, Dickson DW, Bu G (2013) Brain regional correlation of amyloid-beta with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-beta accumulation. Acta Neuropathol 125:535–547. doi:10.1007/s00401-013-1086-9
44. Soontornniyomkij V, Lynch MD, Mermash S, Pomakian J, Badkoobehi H, Clare R, Vinters HV (2010) Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy. Brain Pathol 20:459–467. doi:10.1111/j.1750-3639.2009.00322.x
45. Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y (1994) High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Am J Pathol 145:452–460
46. Thal DR, Papassotiropoulos A, Saido TC, Griffin WS, Mrak RE, Kolsch H, Del Tredici K, Attems J, Ghebremedhin E (2010) Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer’s disease. Acta Neuropathol 120:169–183. doi:10.1007/s00401-010-0707-9
47. Thambisetty M, Beason-Held L, An Y, Kraut MA, Resnick SM (2010) APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch Neurol 67:93–98. doi:10.1001/archneurol.2009.913
48. Vinters HV (1987) Cerebral amyloid angiopathy. A critical review. Stroke 18:311–324
49. Vinters HV, Gilbert JJ (1983) Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 14:924–928
50. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO (2008) Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol 18:253–266. doi:10.1111/j.1750-3639.2008.00133.x
51. Zlokovic BV (2013) Cerebrovascular effects of apolipoprotein e: implications for Alzheimer disease. JAMA Neurol 70:440–444. doi:10.1001/jamaneurol.2013.2152